Abstract Number: 825 • 2015 ACR/ARHP Annual Meeting
Subclinical Atherosclerosis and Estimation of Cardiovascular Risk in Systemic Sclerosis
Background/Purpose: During the last decade, it has been shown that cardiovascular disease (CVD) in systemic sclerosis (SSc) is increased and accounts for ~30% of the…Abstract Number: 1788 • 2015 ACR/ARHP Annual Meeting
Lipoprotein Subfractions and Cardiovascular Disease in Systemic Lupus Erythematosus
Background/Purpose: Risk of atherosclerotic cardiovascular disease (CVD) is significantly enhanced in systemic lupus erythematosus (SLE) compared to age and gender matched controls. While this risk…Abstract Number: 2637 • 2014 ACR/ARHP Annual Meeting
Assessment of Plaque Thickness and Area in Patients with SLE As Measures of Atherosclerosis – Associations with Disease Activity
Background/Purpose SLE is an independent risk factor for cardiovascular disease (CVD). Traditional risk stratification tools underestimate CVD risk in patients with SLE. Previous vascular ultrasound…Abstract Number: 628 • 2014 ACR/ARHP Annual Meeting
The Predictive Value of Cardiovascular and Metabolic Biomarkers for Progression of Atherosclerosis in Psoriatic Disease
Background/Purpose The pathophysiologic mechanisms underlying the accelerated atherosclerosis in patients with psoriatic disease (PsD) are unknown. We aimed to investigate candidate pathways involved in this…Abstract Number: 2617 • 2014 ACR/ARHP Annual Meeting
No Evidence of Accelerated Atheromatosis, Increased Arterial Stiffness or Hypertrophy in Ankylosing Spondylitis: A Systematic Case-Control Study
Background/Purpose: Chronic inflammatory arthritis is associated with increased cardiovascular disease (CVD) risk. The mechanisms behind this link include chronic inflammation, comorbidities and disease-related drugs. CV…Abstract Number: 627 • 2014 ACR/ARHP Annual Meeting
HLA Markers for Disease Severity Are Associated with a Higher Burden of Atherosclerosis in Patients with Psoriatic Disease
Background/Purpose Recent evidence supports the link between the extent of inflammation and cardiovascular risk in patients with psoriatic disease (PsD). We aimed to investigate the…Abstract Number: 2452 • 2014 ACR/ARHP Annual Meeting
Protective Effect of the IL33 rs3939286 Gene Polymorphism in the Development of Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a complex inflammatory disease characterized by chronic inflammation, accelerated atherosclerosis and increased cardiovascular (CV) mortality. Interleukin 33 (IL-33) is a…Abstract Number: 542 • 2014 ACR/ARHP Annual Meeting
Predictors for Cardiovascular Events in Patients with Psoriatic Arthritis – a Cohort Study
Background/Purpose The prevalence of cardiovascular (CV) morbidity is increased in patients with psoriatic arthritis (PsA). CV risk is only partially explained by traditional CV risk…Abstract Number: 1978 • 2014 ACR/ARHP Annual Meeting
Role of Monocytes Subsets in the Pathology of Rheumatoid Arthritis: Involvement in Endothelial Dysfunction and Proinflammatory Profile
Background/Purpose Different frequency of monocytes subsets has been reported in rheumatoid arthritis (RA).Human monocytes are divided into three main subpopulations according to expression of the…Abstract Number: 489 • 2014 ACR/ARHP Annual Meeting
Rosuvastatin Improves Arterial Stiffness in Patients with Inflammatory Joint Diseases
Background/Purpose Arterial stiffness, as pulse wave velocity (PWV) and augmentation index (AIx) has emerged as early risk markers of cardiovascular disease (CVD) in patients with…Abstract Number: 1913 • 2014 ACR/ARHP Annual Meeting
Rosuvastatin Induced Carotid Plaque Regression in Patients with Inflammatory Joint Diseases
Background/Purpose Patients with rheumatoid arthritis (RA) and carotid artery plaques (CP) have increased risk of acute coronary syndromes. Statin treatment with low density lipoprotein cholesterol…Abstract Number: 438 • 2014 ACR/ARHP Annual Meeting
Distinct Profiles of Proinflammatory Macrophages in Rheumatoid Arthritis and Coronary Artery Disease
Background/Purpose: Patients with RA have an increased risk of developing coronary artery disease (CAD) compared to the general population. The underlying pathological process of CAD…Abstract Number: 1633 • 2014 ACR/ARHP Annual Meeting
Galectin-3-Binding Protein Is Associated with Disease Activity, but Not with Atherosclerosis in SLE Patients
Background/Purpose . Patients with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease (CVD), which may be due to an increased prevalence of atherosclerosis.…Abstract Number: 398 • 2014 ACR/ARHP Annual Meeting
Anti-Rheumatic Therapy Decreases Syndecan-1 Shedding in Rheumatoid Arthritis (RA)
Background/Purpose Intact glycocalyx is of importance for healthy endothelial function. Changes in the endothelial glycocalyx, characterized by increased levels of circulating syndecan-1, might be related…Abstract Number: 1591 • 2014 ACR/ARHP Annual Meeting
Exploring the Association of Serum Paraoxonase and Arylesterase Activities with Cardiovascular Risk in Psoriasis and Psoriatic Arthritis
Background/Purpose Psoriatic diseases are systemic inflammatory joint and skin disorders associated with increased cardiovascular (CV) morbidity. Paraoxonase (PON) and Arylesterase (ARYL) are antioxidant enzymatic proteins…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 17
- Next Page »